Evidence map›Paper›PMID 42414029›Full record

ArticleBMJ case reports2026

Case of concurrent ALS and human T-cell leukaemia virus type 1-associated myositis.

Toshika Hata, Nobuhiro Ogawa, Hiroyuki Yabata, Shuhei Kobashi, Misako Nakayama, Hirohito Ishigaki, Isamu Yamakawa, Yasushi Itoh, Ichizo Nishino, Makoto Urushitani

Abstract readCase Reports
In one paragraph

Article in BMJ case reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Toshika HataDepartment of Neurology, Shiga University of Medical Science, Otsu, Japan.
Nobuhiro OgawaDepartment of Neurology, Shiga University of Medical Science, Otsu, Japan.
Hiroyuki YabataDepartment of Neurology, Shiga University of Medical Science, Otsu, Japan.
Shuhei KobashiDepartment of Neurology, Shiga University of Medical Science, Otsu, Japan.
Misako NakayamaPathology, Shiga University of Medical Science, Otsu, Shiga Prefecture, Japan.
Hirohito IshigakiDivision of Pathology and Disease Regulation, Shiga University of Medical Science, Otsu, Japan.
Isamu YamakawaNeurology, Shiga University of Medical Science, Otsu, Shiga Prefecture, Japan.
Yasushi ItohDivision of Pathology and Disease Regulation, Shiga University of Medical Science, Otsu, Japan.
Ichizo NishinoDepartment of Neuromuscular Research, National Center of Neurology and Psychiatry, Kodaira, Tokyo, Japan.
Makoto UrushitaniDepartment of Neurology, Shiga University of Medical Science, Otsu, Japan uru@belle.shiga-med.ac.jp.ORCID http://orcid.org/0000-0003-2773-9836

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

A woman in her late 70s presented with progressive limb weakness, muscle atrophy and hyper-reflexia. Laboratory findings revealed elevated creatine kinase and positive serum human T-cell leukaemia virus type 1 (HTLV-1) antibody. Clinical and electrophysiological findings met revised El Escorial criteria for amyotrophic lateral sclerosis (ALS), but muscle MRI showed inflammatory changes. Muscle biopsy revealed both neurogenic and inflammatory features. While methylprednisolone showed no benefit, intravenous immunoglobulin therapy produced transient improvement in weakness with normalisation of creatine kinase levels. The patient died from respiratory failure 3 years after symptom onset. Autopsy confirmed typical ALS-TDP pathology with phosphorylated TDP-43 inclusions in motor neurons. HTLV-1 Tax-positive lymphocytes infiltrated skeletal muscles but not the central nervous system, establishing dual pathology of ALS-TDP with HTLV-1-associated myositis. The improvement most likely reflected treatment of the HTLV-1-associated myositis rather than the underlying motor neuron disease. This case highlights the importance of evaluating treatable conditions in HTLV-1-seropositive ALS patients.

Indexed as

Amyotrophic Lateral SclerosisHTLV-I InfectionsHuman T-lymphotropic virus 1MyositisAgedFatal OutcomeFemaleHumansImmunoglobulins, IntravenousMagnetic Resonance ImagingMuscle, SkeletalImmunoglobulins, IntravenousAmyotrophic Lateral SclerosisInfection (neurology)Motor neurone diseaseMuscle disease

Identifiers

PMID42414029
PMCPMC13342691

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.